Value
6.1/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 7.3 |
| EV/EBITDA | 3.1 |
| p ocf | 8.2 |
| Analyst target | 6.0 |
- ▸P/OCF: 10.7x (FFO proxy — REITs gated off P/E)
DOC · Why this verdict
Why Healthpeak Properties (DOC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Healthpeak Properties has exceeded its analyst consensus target, leaving no positive asymmetry at current levels; while the portfolio demonstrates strong cash conversion and a high financial health score, heavy geographic concentration in San Francisco laboratory space and a dividend whose safety is in question make this a name to reduce rather than add.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
More than half the portfolio is concentrated in San Francisco laboratory space, a sub-market sensitive to biotech funding cycles; a sustained softening in lab demand in that geography would disproportionately impair occupancy and rental income relative to a more diversified portfolio. Bear case | Diversification away from San Francisco laboratory exposure toward other geographies or healthcare property types, with that market's share falling visibly over 12 months, would reduce the concentration risk. | ↓Deteriorating |
| CounterSan Francisco laboratory real estate benefits from proximity to leading research institutions and a dense biotech cluster; a recovery in life-science funding could rapidly re-lease vacancies and push rents higher, vindicating the concentrated exposure. | ||
The stock is priced above its analyst consensus target, leaving negative upside to that target; with the risk/reward ratio negative at current levels, there is no margin of safety for new buyers and the technical setup does not compensate for the absence of fundamental upside. Price targets | Either the analyst target is raised meaningfully above current prices following a strong funds-from-operations report, or the stock pulls back enough to restore a positive return profile before the setup warrants re-engagement. | →Stable |
| CounterAnalyst targets are revised upward as REITs demonstrate funds-from-operations growth; two consecutive strong earnings beats — like the two most recent quarters delivered — could prompt a meaningful target lift that restores conventional upside. | ||
The dividend yield is flagged as potentially uncovered, undermining the income thesis that is central to the investment case for a healthcare REIT; an uncovered distribution would ultimately require either a cut or continued capital recycling to sustain. Catalyst breakdown | Funds from operations per share visibly exceeding the declared dividend for two consecutive quarters would confirm the distribution is sustainable at current levels and remove the yield-trap concern. | ↑Improving |
| CounterThe portfolio generates free cash flow at 500% of net income, and for a REIT the GAAP net income figure is suppressed by large non-cash depreciation charges; a true funds-from-operations analysis might show the dividend is better covered than headline earnings suggest. | ||
A financial health score of 8 out of 9 and exceptional cash conversion indicate underlying portfolio quality that could support a re-rating if the current gap between price and target resolves through target appreciation rather than price decline. Quality breakdown | Sustained strong cash generation and another earnings beat over the next two quarters would support the case that the portfolio's quality is durable and merits a higher analyst target. | →Stable |
| CounterHigh cash conversion in a REIT partly reflects the non-cash nature of depreciation; absent genuine rent growth and occupancy improvement in the concentrated San Francisco laboratory portfolio, the metric flatters the underlying operational trajectory. | ||
More than half the portfolio is concentrated in San Francisco laboratory space, a sub-market sensitive to biotech funding cycles; a sustained softening in lab demand in that geography would disproportionately impair occupancy and rental income relative to a more diversified portfolio.
↓DeterioratingBear case
- Expectation
- Diversification away from San Francisco laboratory exposure toward other geographies or healthcare property types, with that market's share falling visibly over 12 months, would reduce the concentration risk.
CounterSan Francisco laboratory real estate benefits from proximity to leading research institutions and a dense biotech cluster; a recovery in life-science funding could rapidly re-lease vacancies and push rents higher, vindicating the concentrated exposure.
The stock is priced above its analyst consensus target, leaving negative upside to that target; with the risk/reward ratio negative at current levels, there is no margin of safety for new buyers and the technical setup does not compensate for the absence of fundamental upside.
→StablePrice targets
- Expectation
- Either the analyst target is raised meaningfully above current prices following a strong funds-from-operations report, or the stock pulls back enough to restore a positive return profile before the setup warrants re-engagement.
CounterAnalyst targets are revised upward as REITs demonstrate funds-from-operations growth; two consecutive strong earnings beats — like the two most recent quarters delivered — could prompt a meaningful target lift that restores conventional upside.
The dividend yield is flagged as potentially uncovered, undermining the income thesis that is central to the investment case for a healthcare REIT; an uncovered distribution would ultimately require either a cut or continued capital recycling to sustain.
↑ImprovingCatalyst breakdown
- Expectation
- Funds from operations per share visibly exceeding the declared dividend for two consecutive quarters would confirm the distribution is sustainable at current levels and remove the yield-trap concern.
CounterThe portfolio generates free cash flow at 500% of net income, and for a REIT the GAAP net income figure is suppressed by large non-cash depreciation charges; a true funds-from-operations analysis might show the dividend is better covered than headline earnings suggest.
A financial health score of 8 out of 9 and exceptional cash conversion indicate underlying portfolio quality that could support a re-rating if the current gap between price and target resolves through target appreciation rather than price decline.
→StableQuality breakdown
- Expectation
- Sustained strong cash generation and another earnings beat over the next two quarters would support the case that the portfolio's quality is durable and merits a higher analyst target.
CounterHigh cash conversion in a REIT partly reflects the non-cash nature of depreciation; absent genuine rent growth and occupancy improvement in the concentrated San Francisco laboratory portfolio, the metric flatters the underlying operational trajectory.
Per-dimension breakdown
Quality
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 1.0 |
| ROA | 1.0 |
| Gross margin | 7.5 |
| Op margin | 6.4 |
| Net margin | 4.1 |
| Current ratio | 7.9 |
| FCF quality | 10.0 |
| Moat | 6.4 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 676% FCF/NI
- ▸Strong Piotroski F-Score: 8/9
Growth
7.7/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.3 |
| EPS growth | 10.0 |
Momentum
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 7.5 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 1.7 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+3.0%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.5 |
| Price target | 7.8 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 21%
Insider
3.6/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 2.7 |
| notable moves | 3.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.2 |
| quality rank | 4.3 |
| growth rank | 4.0 |
Technical
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.4 |
| support resistance | 8.0 |
| 52w position | 6.4 |
Risk (lower is worse)
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.0 |
| days to cover | 7.2 |
| volatility | 6.0 |
| put call | 9.3 |
| implied vol | 3.7 |
| max pain risk | 3.0 |
| beta | 7.1 |
| debt equity | 4.8 |
- ▸Above max pain $12
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 5.2 |
- ▸Strong earnings: 3B/1M
- ▸Earnings in 4 days
- ▸Dividend: 6.4%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- ASYMMETRY:1.7>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.4<4.5
- EARNINGS_PROXIMITY:4d<=7d
Warning (0)
none
Reward-to-Risk
1.66
Upside
+8.7%
Downside
5.2%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 7.7) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:3.4<4.5, EARNINGS_PROXIMITY:4d<=7d) reinforce the read. Current asymmetry R:R is 1.66 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 7.7, Technical at 7.3, and Sentiment at 6.9; the weakest are Momentum at 3.4, Insider at 3.6, and Peer rank at 3.9. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 1.66 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Price Above Analyst Target
Trip ifAnalyst consensus target rises above $23.00, restoring more than 10% upside from current price levels.
- P2Sf Lab Portfolio Concentration
Trip ifSan Francisco laboratory portfolio exposure falls below 40% of total portfolio value within 24 months.
- P3Dividend Safety Concern
Trip ifFFO per share exceeds the declared dividend by more than 1.2x for 2 consecutive quarters.
- P4Strong Underlying Quality
Trip ifCash conversion falls below 200% of net income for 2 consecutive quarters.